The American Thoracic Society's International Conference (ATS) – one of the largest gatherings of pulmonary, critical care, and sleep medicine professionals in the world – held its 113th ATS-Conference in Washington, D.C., 19th-24th May 2017. 

A new webinar series aimed at providing easy-to-understand information about idiopathic pulmonary fibrosis (IPF).

With Prof. Dr. Claus-Peter Heussel and Prof. Dr. Michael Kreuter, both from the Thoraxklinik, University of Heidelberg, Germany.

Follow the links to discover further information about meetings and congresses.

International congresses enable clinicians to keep up with advances in research and can be a great source of information for healthcare professionals. That said, the magnitude of data presented and discussed can be overwhelming and not everyone has the opportunity to visit those congresses.

You may find the following example patient auscultations useful to compare the differences between idiopathic pulmonary fibrosis (IPF) and other pulmonary diseases.

The following online resources are useful for HCPs interested in idiopathic pulmonary fibrosis (IPF) research and clinical practice. For resources for patients and others affected by IPF, please visit our resources for patients page.

The first clinical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis (IPF)1 were published in 2011. In July 2015, the treatment recommendations were updated according to evidence reported since the publication of the prior guidelines.2

The American Thoracic Society's International Conference (ATS) – one of the largest gatherings of pulmonary, critical care, and sleep medicine professionals in the world – was held May 13th-18th in San Francisco, California.

The European Respiratory Society (ERS) – one of the leading international organisations in the respiratory field – brought together specialists working in respiratory medicine at its annual international congress in London, United Kingdom (September 3rd - 7th 2016).

Few patients immediately understand the true implications of a diagnosis of IPF.

The book "Understanding Your Body – Idiopathic Pulmonary fibrosis (IPF)" explains IPF in an easy-to-understand way and  covers necessary examinations and treatment options.

You may find the following videos useful for finding out more about idiopathic pulmonary fibrosis (IPF).

Our library of IPF patients cases taken from real clinical experience allows you to familiarise yourself with the process of IPF diagnosis and treatment.

 OFEV® (nintedanib) approved in the EU for the treatment of IPF

IPF is not curable, but a number of pharmacological treatment options and therapeutic strategies for patients to manage their condition exist.

The key to diagnosing idiopathic pulmonary fibrosis (IPF) is a high-resolution computed-tomography (HRCT) scan. If the HRCT scan shows a usual interstitial pneumonia (UIP) pattern and alternative causes of interstitial lung disease (ILD) can be ruled out, a diagnosis of IPF is indicated.

Use our audio resources to listen to IPF associated lung velcro crackles and sounds related to other lung conditions.

Learn what is required for a conclusive IPF diagnosis.

Explore our ePatCare® ILD software tool, designed to strengthen the dialogue between pulmonologists and healthcare professionals in respiratory disease.

In order to conclusively diagnose IPF, a number of other lung diseases must be excluded. 

Learn about key symptoms in IPF diagnosis.

IPF patients experience intrusive symptoms and reduced functional capacity that impact their quality of life.

Test your ear! Can you identify IPF in our Sound challenge?

Common IPF symptoms include dyspnoea, dry cough, velcro crackles on lung auscultation and finger clubbing.

Study overview

IPF is a rare disease with in incidence of 5-10 people per 100.000 population, and a prevalence of 14-43 people per 100.000 population.

IPF is a chronic, progressive and debilitating disease, characterised by inflammation and scarring of lung tissue resulting in loss of lung function and impaired gas exchange over time.

Interstitial lung diseases (ILDs) are referred to as a heterogeneous entity of over 150 lung diseases that have in common to affect the connective tissue giving shape and supportive structure to the lungs (“interstitium”). This interstitium encompasses the alveolar epithelium as well as the interstitial capillaries and the surrounding soft tissue. Many diseases in the group of ILDs are connected to the development of pulmonary fibrosis, which might evolve also at a very late stage.1

The European Respiratory Society (ERS) is one of the leading medical organisations in the respiratory field centering on research, education and advocacy. The International ERS Congress is one of the most significant gatherings in respiratory healthcare with international leaders in the field presenting the latest scientific developments.